Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | HMOX2 | P30519 | 1/20 | 1.00 |
| ▸ | CRYZ | Q08257 | 1/20 | 1.00 |
| ▸ | VAT1 | Q99536 | 1/20 | 1.00 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379971 | 1.00 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16637284 | 1.00 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL31658077 | 0.97 | KRAS (0.93) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128690 | 0.97 | KRAS (0.93) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765662 | 0.94 | KRAS (0.88) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16647182 | 0.94 | KRAS (0.88) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29766035 | 0.92 | KRAS (0.84) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16646915 | 0.92 | KRAS (0.84) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18842314 | 0.91 | KRAS (0.83) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL21471922 | 0.90 | KRAS (0.82) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130891-A1 | PIM KINASE INHIBITOR IN COMBINATION WITH KRAS INHIBITOR | NINGBO NEWBAY TECH DEVELOPMENT CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-20260109786-A1 | CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-23 | — | — | US | claimed |
| US-12605383-B2 | Methods of treating cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-04-21 | — | — | US | claimed |
| US-20260102528-A1 | BINDING AGENT RECOGNITION OF DRUG-PEPTIDE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-16 | — | — | US | claimed |
| EP-4719410-A1 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12486334-B2 | Chemically controlled monoclonal antibody target engagement | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | claimed |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025226775-A2 | COMPOSITIONS AND METHODS FOR BINDING TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4635574-A2 | COMBINATION THERAPY TO TREAT KRAS MUTANT CANCERS | Semmelweis Egyetem (HU) | 2025-10-22 | — | — | EP | claimed |
| WO-2022183112-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114901286-A | Combination therapy involving diaryl macrocycle compounds | 特普医药公司 | 2022-08-12 | — | — | CN | claimed |
| EP-4010081-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-06-15 | — | — | EP | claimed |
| WO-2022119349-A1 | COMPOSITION FOR SUPPRESSING RESISTANCE TO KRAS INHIBITOR | 울산대학교 산학협력단 | 2022-06-09 | — | — | WO | claimed |
| WO-2022115767-A1 | METHODS OF TREATING CANCER | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-02 | — | — | WO | claimed |
| EP-3997131-A1 | CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT | The Regents of the University of California (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220112308-A1 | KRAS SPECIFIC ANTIBODIES AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-14 | — | — | US | claimed |
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109786-A1 | CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT | SET, TNFSF11, TNFSF10 | KRAS 849/4885EGFR 62/4885HMOX2 4308/4885 |
| US-20260102528-A1 | BINDING AGENT RECOGNITION OF DRUG-PEPTIDE CONJUGATES | IGSF11, PDCD1LG2, CD79B | KRAS 1214/4885EGFR 962/4885HMOX2 4138/4885 |
| US-20260130891-A1 | PIM KINASE INHIBITOR IN COMBINATION WITH KRAS INHIBITOR | KRAS, PIM1, PIM3 | KRAS 1/4885EGFR 121/4885HMOX2 2454/4885 |
| US-12605383-B2 | Methods of treating cancer | IL36G, IL2RA, TP53 | KRAS 4/4885EGFR 20/4885HMOX2 3289/4885 |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | MICA, CD74, HLA-DRB1 | KRAS 2277/4885EGFR 2295/4885HMOX2 4242/4885 |
| US-12486334-B2 | Chemically controlled monoclonal antibody target engagement | TP53, CD47, BCR | KRAS 51/4885EGFR 28/4885HMOX2 3517/4885 |
| US-20220112308-A1 | KRAS SPECIFIC ANTIBODIES AND USES THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 137/4885HMOX2 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.